Baricitinib in New Onset Type 1 Diabetes (BANDIT)
BANDIT is a clinical trial testing a drug called baricitinib that has the potential to slow or stop the destruction of beta cells in people with T1D.
Participants in the BANDIT trial must be between the ages of 12 – 30 years old, and must have been diagnosed with type 1 diabetes within the last 100 days.
Participants will be required to attend at one of four sites in Melbourne or Adelaide: The Royal Melbourne Hospital, The Royal Children’s Hospital, St Vincent’s Hospital Melbourne or the Women’s and Children’s Hospital Adelaide.
BANDIT has been approved by the Melbourne Health Human Research Ethics Committee (HREC).
ANZCTR listing: ACTRN12620000239965